Sorafenib provided longer survival than lenvatinib in patients> 60 years of age (HR = 1.84, 95% CI 1.01–3.36, p = 0.044), AFP ≤ 200 ng/mL (HR = 2.09, 95% CI 1.16–3.76, p = 0.012), and tumor size ≤ 5 cm (HR = 2.39, 95% CI 1.13–5.04, p = 0.019; Fig. 5). This evidence concerns the gene AFP and neoplasm.